Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume $107.74 +1.98 (+1.87%) As of 01:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Ligand Pharmaceuticals Short Interest DataLigand Pharmaceuticals (LGND) has a short interest of 1.01 million shares, representing 5.68% of the float (the number of shares available for trading by the public). This marks a 5.75% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.0, indicating that it would take 9.0 days of the average trading volume of 120,292 shares to cover all short positions.Current Short Interest1,010,000 sharesPrevious Short Interest955,100 sharesChange Vs. Previous Month+5.75%Dollar Volume Sold Short$106.19 millionShort Interest Ratio9.0 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares19,255,000 sharesShort Percent of Float5.68%Today's Trading Volume20,827 sharesAverage Trading Volume120,292 sharesToday's Volume Vs. Average17% Short Selling Ligand Pharmaceuticals? Sign up to receive the latest short interest report for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLGND Short Interest Over TimeLGND Days to Cover Over TimeLGND Percentage of Float Shorted Over Time Ligand Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/20251,010,000 shares $106.19 million +5.8%5.7%9 $105.14 3/15/2025955,100 shares $101.42 million +22.4%5.4%8.3 $106.19 2/28/2025780,100 shares $95.35 million -7.7%4.4%7.1 $122.23 2/15/2025845,000 shares $101.40 million -11.2%4.8%8 $120.00 1/31/2025951,500 shares $110.90 million +4.4%N/A8.2 $116.55 1/15/2025911,400 shares $100.51 million +1.3%N/A7.4 $110.28 12/31/2024900,100 shares $96.45 million +10.7%N/A7.5 $107.15 12/15/2024812,800 shares $95.02 million +3.5%N/A6.9 $116.91 11/30/2024785,700 shares $95.44 million -5.5%N/A7.1 $121.47 11/15/2024831,500 shares $92.89 million -9.5%N/A7.5 $111.71 Get the Latest News and Ratings for LGND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 10/31/2024918,600 shares $97.10 million -8.1%N/A8.5 $105.70 10/15/20241,000,000 shares $104.39 million +0.4%N/A9.5 $104.39 9/30/2024996,100 shares $99.70 million +1.9%N/A8.7 $100.09 9/15/2024977,400 shares $102.40 million -1.8%N/A7.9 $104.77 8/31/2024995,000 shares $105.27 million -6.1%N/A8.1 $105.80 8/15/20241,060,000 shares $109.32 million +10.3%N/A8.3 $103.13 7/31/2024960,700 shares $104.71 million -12.7%N/A6.9 $108.99 7/15/20241,100,000 shares $106.34 million +17.7%N/A7.9 $96.67 6/30/2024934,400 shares $78.73 million -0.2%N/A6.5 $84.26 6/15/2024936,600 shares $74.98 million +32.3%N/A6.6 $80.06 5/31/2024707,700 shares $60.19 million -17.6%N/A4.3 $85.05 5/15/2024858,700 shares $73.65 million +7.9%N/A4.6 $85.77 4/30/2024795,600 shares $55.60 million -3.8%N/A4.3 $69.89 4/15/2024826,600 shares $65.94 million +23.0%5.0%4.9 $79.77 3/31/2024672,100 shares $49.13 million -23.3%4.1%4.1 $73.10 3/15/2024876,300 shares $62.30 million +14.9%5.3%5.8 $71.09 2/29/2024762,600 shares $60.51 million -15.0%4.6%5.3 $79.35 2/15/2024896,600 shares $66.93 million -3.6%5.5%7.3 $74.65 1/31/2024929,800 shares $67.97 million +1.0%5.7%8.1 $73.10 1/15/2024920,700 shares $66.84 million +2.2%6.9%8.2 $72.60 12/31/2023900,800 shares $64.34 million +0.8%5.5%8.2 $71.42 12/15/2023893,600 shares $60.18 million -1.7%5.5%8.1 $67.35 11/30/2023909,100 shares $53.01 million -2.3%5.5%8.8 $58.31 11/15/2023930,200 shares $52.54 million +6.1%5.7%9.2 $56.48 10/31/2023876,400 shares $45.83 million +3.8%5.4%8.8 $52.29 10/15/2023844,700 shares $46.45 million +2.5%5.2%8.8 $54.99 9/30/2023824,100 shares $49.38 million -0.1%5.1%8.4 $59.92 9/15/2023825,000 shares $51.13 million -6.2%5.1%8.8 $61.98 8/31/2023879,200 shares $57.82 million +4.6%5.4%9.1 $65.77 8/15/2023840,500 shares $56.81 million +4.3%5.2%8.6 $67.59Trump to redistribute trillions of dollars (Ad)This playbook is something my connections and I have been discussing in private ever since we met with Trump at Mar-a-Lago last year. And while Trump has never formally acknowledged this plan, if you connect the dots on the chaos he’s been sowing, it’s obvious. Everything you need to know is laid out for you here. 7/31/2023805,800 shares $53.93 million -3.4%5.0%8.2 $66.93 7/15/2023834,300 shares $56.61 million -1.4%5.1%8.4 $67.85 6/30/2023846,200 shares $61.01 million +4.0%5.2%8.6 $72.10 6/15/2023814,000 shares $64.30 million -1.6%5.0%7.8 $78.99 5/31/2023827,100 shares $57.96 million +1.3%5.1%7.9 $70.08 5/15/2023816,400 shares $63.34 million +0.7%5.0%7.2 $77.59 4/30/2023811,100 shares $61.93 million +5.1%5.1%7 $76.35 4/15/2023771,800 shares $57.38 million -1.0%4.8%6.6 $74.34 3/31/2023779,200 shares $57.32 million -13.5%4.9%6.5 $73.56 3/15/2023900,500 shares $64.48 million +7.5%5.6%7.1 $71.61 2/28/2023838,100 shares $60.46 million +2.5%5.2%5.1 $72.14 2/15/2023817,900 shares $59.69 million +1.5%5.1%4.8 $72.98 1/31/2023806,000 shares $56.18 million +0.1%5.1%4.6 $69.70 1/15/2023805,000 shares $57.38 million +1.5%5.1%4.1 $71.28 12/30/2022792,800 shares $52.96 million -8.4%5.0%4.1 $66.80 12/15/2022865,800 shares $53.81 million +13.0%5.5%4.4 $62.15 11/30/2022766,100 shares $55.85 million -2.3%4.8%4.6 $72.90 11/15/2022784,100 shares $61.99 million +6.6%4.9%5 $79.06 10/31/2022735,400 shares $64.46 million -0.3%4.6%5 $87.65 10/15/2022737,800 shares $66.03 million -6.7%4.6%6 $89.49 9/30/2022790,600 shares $68.08 million -5.1%5.0%6.6 $86.11 9/15/2022833,000 shares $75.08 million +3.1%5.2%7 $90.13 8/31/2022808,200 shares $74.67 million -3.7%5.1%6.6 $92.39 8/15/2022839,000 shares $90.03 million -3.2%5.3%6.8 $107.31 7/31/2022866,700 shares $79.76 million -0.8%5.4%6.5 $92.03 7/15/2022873,600 shares $82.58 million -3.6%5.4%6 $94.53 6/30/2022905,800 shares $80.82 million -0.2%5.6%6 $89.22 6/15/2022907,900 shares $71.80 million -0.6%N/A5.7 $79.08 5/31/2022913,400 shares $81.21 million -10.5%5.7%6.2 $88.91 5/15/20221,020,000 shares $87.68 million -8.9%6.4%6.2 $85.96 4/30/20221,120,000 shares $104.00 million No Change7.0%6.8 $92.86 4/15/20221,120,000 shares $117.89 million -8.9%7.0%6.8 $105.26 3/31/20221,230,000 shares $138.36 million +2.5%7.7%7.2 $112.49 3/15/20221,200,000 shares $125.44 million -2.4%7.5%7.5 $104.53 2/28/20221,230,000 shares $124.50 million No Change7.7%7.7 $101.22 2/15/20221,230,000 shares $152.13 million -10.2%7.8%8.1 $123.68 1/31/20221,370,000 shares $170.74 million -11.0%8.6%9.7 $124.63 1/15/20221,540,000 shares $192.36 million -4.4%9.7%11.3 $124.91 12/31/20211,610,000 shares $248.68 million -4.2%10.1%13.4 $154.46 12/15/20211,680,000 shares $247.80 million +5.0%10.6%13.9 $147.50 11/30/20211,600,000 shares $259.07 million +0.6%10.1%13.5 $161.92 11/15/20211,590,000 shares $260.93 million -4.2%10.0%8 $164.11 10/29/20211,660,000 shares $242.26 million No Change10.5%8 $145.94 10/15/20211,660,000 shares $216.23 million -4.1%10.5%7.9 $130.26 9/30/20211,730,000 shares $241.02 million -2.8%10.9%8 $139.32 9/15/20211,780,000 shares $241.83 million +10.6%11.2%7.8 $135.86 8/31/20211,610,000 shares $213.00 million -0.6%10.2%7 $132.30 8/13/20211,620,000 shares $173.05 million -1.8%10.2%10.1 $106.82 7/30/20211,650,000 shares $187.29 million -6.3%10.4%11 $113.51 7/15/20211,760,000 shares $203.84 million +0.6%11.1%11.7 $115.82Trump to redistribute trillions of dollars (Ad)This playbook is something my connections and I have been discussing in private ever since we met with Trump at Mar-a-Lago last year. And while Trump has never formally acknowledged this plan, if you connect the dots on the chaos he’s been sowing, it’s obvious. Everything you need to know is laid out for you here. 6/30/20211,750,000 shares $229.58 million +1.7%11.0%11.7 $131.19 6/15/20211,720,000 shares $212.97 million +8.2%10.8%12 $123.82 5/28/20211,590,000 shares $187.14 million -0.6%10.0%9.8 $117.70 5/14/20211,600,000 shares $198.21 million -0.6%10.1%8.5 $123.88 4/30/20211,610,000 shares $234.69 million +2.6%10.1%6.1 $145.77 4/15/20211,570,000 shares $237.12 million +4.7%9.9%2.9 $151.03 3/31/20211,500,000 shares $223.67 million -19.4%9.5%2.6 $149.11 3/15/20211,860,000 shares $306.49 million -15.8%11.8%3 $164.78 2/26/20212,210,000 shares $331.96 million -19.3%14.0%3.6 $150.21 2/12/20212,740,000 shares $493.31 million -54.1%17.9%4.5 $180.04 1/29/20215,970,000 shares $1.14 billion -40.4%38.9%10.3 $191.59 1/15/202110,010,000 shares $1.22 billion +1.0%64.9%21.5 $122.28 12/31/20209,910,000 shares $1.02 billion -0.7%64.2%28.9 $102.63 12/15/20209,980,000 shares $1.02 billion -1.6%64.7%29.5 $101.79 11/30/202010,140,000 shares $871.23 million -4.6%65.7%30.6 $85.92 11/15/202010,630,000 shares $889.84 million -1.0%68.9%32.7 $83.71 10/30/202010,740,000 shares $892.17 million +5.1%69.6%34.8 $83.07 10/15/202010,220,000 shares $1.02 billion +3.9%66.2%34.7 $100.01 9/30/20209,840,000 shares $937.95 million +6.0%63.8%39.7 $95.32 9/15/20209,280,000 shares $890.79 million +3.0%60.1%35 $95.99 8/31/20209,010,000 shares $919.02 million +0.9%58.4%34.6 $102.00 8/14/20208,930,000 shares $1.01 billion +4.6%57.9%31.6 $113.25 7/31/20208,540,000 shares $1.00 billion -3.3%55.5%27.5 $117.18 7/15/20208,830,000 shares $1.05 billion -1.9%57.3%26.7 $119.42 6/30/20209,000,000 shares $1.01 billion -4.8%58.3%24.6 $111.85 6/15/20209,450,000 shares $1.05 billion +2.1%61.2%22.3 $111.49 5/29/20209,260,000 shares $940.54 million -1.9%59.7%17.9 $101.57 5/15/20209,440,000 shares $932.20 million +2.8%60.9%16.8 $98.75 4/30/20209,180,000 shares $904.87 million -2.9%59.2%16.3 $98.57 LGND Short Interest - Frequently Asked Questions What is Ligand Pharmaceuticals' current short interest? Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 1,010,000 shares of LGND short. 5.68% of Ligand Pharmaceuticals' shares are currently sold short. Learn More on Ligand Pharmaceuticals' current short interest. What is a good short interest ratio for Ligand Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 9.0. Learn More on Ligand Pharmaceuticals's short interest ratio. Which institutional investors are shorting Ligand Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ligand Pharmaceuticals: Citadel Advisors LLC, Concourse Financial Group Securities Inc., Walleye Trading LLC, Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Ligand Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.68% of Ligand Pharmaceuticals' floating shares are currently sold short. Is Ligand Pharmaceuticals' short interest increasing or decreasing? Ligand Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,010,000 shares, an increase of 5.7% from the previous total of 955,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Ligand Pharmaceuticals' short interest compare to its competitors? 5.68% of Ligand Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Ligand Pharmaceuticals: Halozyme Therapeutics, Inc. (7.54%), Repligen Co. (6.68%), Madrigal Pharmaceuticals, Inc. (23.76%), Ionis Pharmaceuticals, Inc. (8.63%), Alkermes plc (7.11%), Amicus Therapeutics, Inc. (6.33%), BioCryst Pharmaceuticals, Inc. (10.51%), Dynavax Technologies Co. (14.43%), MannKind Co. (9.69%), Celldex Therapeutics, Inc. (13.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Ligand Pharmaceuticals stock? Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading down $0.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Ligand Pharmaceuticals? A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further. How often is Ligand Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Halozyme Therapeutics Short Interest Data Repligen Short Interest Data Madrigal Pharmaceuticals Short Interest Data Ionis Pharmaceuticals Short Interest Data Alkermes Short Interest Data Amicus Therapeutics Short Interest Data BioCryst Pharmaceuticals Short Interest Data Dynavax Technologies Short Interest Data MannKind Short Interest Data Celldex Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LGND) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGND Stock Free LGND Stock Alerts